HC Wainwright & Co. Maintains Buy on Kinnate Biopharma, Lowers Price Target to $24
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Kinnate Biopharma (NASDAQ:KNTE) but lowers the price target from $25 to $24.
May 18, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Kinnate Biopharma (NASDAQ:KNTE) while lowering the price target from $25 to $24.
The news of HC Wainwright & Co. maintaining a Buy rating on Kinnate Biopharma is positive for the stock. However, the lowering of the price target from $25 to $24 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100